Our results demonstrate EP4 as a potent therapeutic target in cervical cancer and can be effective in combination with conventional therapies to attain superior outcomes and to overcome complications associated with organ toxicities, therapeutic resistance and disease relapse. This evidence concerns the gene PTGER4 and cervical carcinoma.